All Pharma News
NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market
GLOBENEWSWIRE
28 Jun 2024
Share Share
Santen Agrees to Licensing Agreements for its Pharmaceutical Products

Santen Agrees to Licensing Agreements for its Pharmaceutical Products
BUSINESSWIRE
18 Jul 2023
Share Share
Santen Announces Health Canada Approval for Cationorm

Santen Announces Health Canada Approval for Cationorm
BUSINESSWIRE
06 Oct 2022
Share Share
Santen and UBE gain FDA approval for Omlonti eye drops

Santen and UBE gain FDA approval for Omlonti eye drops
Kevin Dunleavy FIERCEPHARMA
28 Sep 2022
Share Share
FDA approves Santen glaucoma drug Omlonti

FDA approves Santen glaucoma drug Omlonti
BUSINESSWIRE
26 Sep 2022
Share Share
Santen launches Ducressa for post-cataract surgery

Santen launches Ducressa for post-cataract surgery
John Pinching PHARMATIMES
15 Aug 2022
Share Share
Santen’s Verkazia 0.1% Now Available for Vernal Keratoconjunctivitis

Santen’s Verkazia 0.1% Now Available for Vernal Keratoconjunctivitis
BUSINESSWIRE
02 May 2022
Share Share
Aerie Concludes Exclusive License Agreement With Santen for Rhopressa, Rocklatan

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa, Rocklatan
PRESS RELEASE
07 Dec 2021
Share Share
Recall of one batch of Ikervis Eye Drops, Emulsion 1mg/ml

Recall of one batch of Ikervis Eye Drops, Emulsion 1mg/ml
HSA
27 Aug 2021
Share Share
Santen and Sydnexis execute an exclusive licensing agreement for SYD-101

Santen and Sydnexis execute an exclusive licensing agreement for SYD-101
PRESS RELEASE
10 Aug 2021
Share Share